Inovio Pharmaceuticals Inc. (NASDAQ:INO) does about 32.57M shares in volume on a normal day but saw 19961157 shares change hands in Monday trading. The company now has a market cap of 2.16B USD. Its current market price is $12.24, marking a decrease of -13.19% compared to the previous close of $14.10. The 52 week high reached by this stock is $33.79 whilst the lowest price level in 52 weeks is $1.91. The script in recent trading has seen the stock touch a high of $13.3565 and a low of $11.93.
Inovio Pharmaceuticals Inc. (INO) has a 20-day trading average at $17.26 and the current price is -63.78% off the 52-week high compared with 539.16% distance from its 52-week low. The 50-day simple moving average of the closing price is $20.53 and its 200-day simple moving average is $10.19. If we look at the stock’s price movements over the week, volatility stands at 7.09%, which increases to 10.29% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 28.23 to suggest the stock is oversold.
8 analysts observing the Inovio Pharmaceuticals Inc. (INO) stock have set the 12-month price targets for the company’s shares at between $8.00 and $36.00. The consensus objective for the share price is $19.00, suggesting that the stock has a potential upside of 35.58% over the period. The median price target is 25.82% away from the current levels at $16.50.
FactSet Research has provided data showing that 8 brokerages have issued ratings for the stock. 1 analysts have rated it as a sell, while 0 advise that it is a overweight. 2 analysts have rated it as a buy and 5 have advised that investors hold their positions. The consensus recommendation rating is Hold and Wall Street’s advice is for investors to Moderate Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on July 01, 2020 when ROTH Capital downgraded the stock to “Sell” and issued a price target of $11. Maxim Group also downgraded the stock to “Hold” from Buy on July 01, 2020 at a price target of.
The current price level is -30.86%, -40.44%, and 20.74% away from its SMA20, SMA50, and SMA200 respectively, with the INO price moving above the 50-day SMA on August 24. Inovio Pharmaceuticals Inc. (INO) stock is down -18.62% over the week and -44.14% over the past month. Its price is 270.91% year-to-date and 461.47% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/29/2020, with the company’s earnings per share (EPS) of -$0.83 below consensus estimates by -$0.66. The company’s next earnings report is expected on 11/04/2020, with forecasts estimating quarterly EPS at -$0.19 and -$1.47 for whole year. INO’s earnings per share are forecast to shrink by -21.50% this year and 140.80% over next year. Expected sales for next quarter are $4.91 million, which analysts say will come at $9.48 million for the current fiscal year and next year at $353.59 million. In addition, estimates put the company’s current quarterly revenue at an average of $3.05 million.
Its 12-month price target is $16.50. To reach the target analysts have set, the stock logically needs to grow 35.58 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $8.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $36.00.
Outstanding shares total 167.52M with insiders holding 2.69% of the shares and institutional holders owning 29.41% of the company’s common stock. The company has a return on investment of -137.90% and return on equity of -217.80%. The forward price to earnings ratio is 20.23. The beta has a value of 1.30. Price to book ratio is 10.20 and price to sales ratio is 800.36.
According to a U.S. Securities and Exchange Commission filing, SPDR S&P Biotech ETF has reduced its position in Inovio Pharmaceuticals Inc. (INO) to 4,460,851 shares, mirroring a recent drop by -0.99%. SPDR S&P Biotech ETF dumped 44688.0 shares of Inovio Pharmaceuticals Inc. common stock bringing its total worth to about $86.72 million at the end of recent close, SEC documents show. SPDR S&P Biotech ETF isn’t the only investment manager who changed stakes and is followed by Vanguard Total Stock Market Index, which sold off 31887.0 shares to end up with 4,261,859 shares worth $82.85 million. iShares Russell 2000 ETF cut their holdings by -4.47% in the company over the course of the most recent quarter. It now holds a 1.87% position in Inovio Pharmaceuticals Inc. thanks to 2.96 million shares amounting to $57.59 million.